Genitourinary Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia), By Product (Hormonal Therapy, Gynecological, Urologicals, Anti-infectives, others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 28.79 Billion
CAGR (2026-2031)	2.59%
Fastest Growing Segment	Hormonal Therapy
Largest Market	North America
Market Size (2031)	USD 33.56 Billion

Market Overview

The Global Genitourinary Drugs Market will grow from USD 28.79 Billion in 2025 to USD 33.56 Billion by 2031 at a 2.59% CAGR. Genitourinary drugs encompass pharmaceutical formulations designed to treat disorders of the urinary tract and reproductive system, including benign prostatic hyperplasia, urinary incontinence, and genitourinary malignancies. The market is fundamentally driven by aging global demographics susceptible to chronic urological conditions and a rising incidence of cancer which necessitates long-term pharmacological management. According to the American Cancer Society, in 2025, an estimated 313,780 new cases of prostate cancer are projected to be diagnosed in the United States. This statistical evidence underscores the critical and growing necessity for sustained therapeutic interventions in this sector.

A primary challenge restricting market expansion is the patent expiration of blockbuster genitourinary medications. The loss of market exclusivity facilitates the entry of cost-effective generic competitors, which significantly reduces revenue streams for established pharmaceutical firms and intensifies pricing pressure. Consequently, companies must navigate stringent regulatory approvals and high development costs to bring novel compounds to market, creating a financial barrier that can slow overall industry growth.

Key Market Drivers

The rising prevalence of genitourinary malignancies, particularly bladder and prostate cancers, acts as a primary catalyst for market demand. As the global population ages, the incidence of these conditions has surged, necessitating extensive pharmacological interventions ranging from intravesical therapies to systemic chemotherapies. According to the World Health Organization, in February 2024, in its latest global cancer burden estimates, an estimated 614,298 new cases of bladder cancer were diagnosed worldwide in 2022, highlighting the substantial patient pool requiring treatment. This burden is further amplified by prostate cancer, which remains a leading indication; according to the American Cancer Society, in April 2024, in the 'Global Cancer Statistics, 2024' report, prostate cancer represented 7.3% of all newly diagnosed cancer cases globally. This escalating disease burden ensures a continuous requirement for effective urological pharmaceuticals to manage both early-stage and metastatic disease.

Advancements in biologics and targeted drug delivery systems are significantly reshaping the competitive landscape and driving revenue growth. Pharmaceutical developers are increasingly shifting focus from conventional chemotherapies to antibody-drug conjugates (ADCs) and immune checkpoint inhibitors that offer improved efficacy for refractory cases. A prime example of this commercial success is the rapid uptake of novel therapies for urothelial carcinoma. According to Astellas Pharma Inc., in April 2025, in the 'Financial Results for Fiscal Year 2024' report, global sales of its targeted therapy Padcev reached ¥164.1 billion, representing a year-on-year growth of 92%. These innovations not only improve patient outcomes but also command premium pricing, thereby expanding the overall value of the genitourinary drugs market.

Download Free Sample Report

Key Market Challenges

The expiration of patent exclusivity for blockbuster medications constitutes a formidable barrier to the financial expansion of the global genitourinary drugs market. When market exclusivity for established therapies used in treating prostate cancer or benign prostatic hyperplasia ends, the immediate influx of lower-cost generic competitors and biosimilars leads to a rapid erosion of market share for originator companies. This commoditization significantly lowers the total monetary value of the sector, as the premium pricing structures of branded drugs are replaced by the marginal costs of generics, directly reducing the overall revenue streams essential for industry growth.

This contraction in revenue creates a volatile environment where pharmaceutical firms face reduced capital availability for the high-risk research and development required to bring novel urological compounds to regulatory approval. The scale of this value transfer from branded revenue to system savings is substantial. According to the Association for Accessible Medicines, in 2025, the utilization of biosimilar medicines generated $20.2 billion in savings during the preceding year. This figure illustrates the profound financial impact of loss of exclusivity, confirming that the sharp decline in per-unit revenue hampers the broader market’s ability to sustain consistent economic growth.

Key Market Trends

The integration of radioligand therapies for metastatic prostate cancer represents a transformative shift in precision oncology by delivering targeted radiation directly to prostate-specific membrane antigen positive cells. This modality offers a potent alternative for patients who have progressed on androgen receptor pathway inhibitors and taxane-based chemotherapy, moving the market beyond traditional systemic treatments. The commercial impact of this class is evident in the rapid market uptake of novel radiopharmaceuticals. According to Novartis, in October 2024, in the 'Q3 2024 Financial Results' report, sales of its radioligand therapy Pluvicto reached $386 million for the quarter, reflecting a 50% increase compared to the previous year. This surge highlights the growing clinical adoption of radioligands as a standard of care for advanced prostate malignancies.

The expansion of PARP inhibitors in castration-resistant prostate cancer is redefining therapeutic protocols by exploiting synthetic lethality in tumors with homologous recombination repair gene mutations. This trend emphasizes a move toward biomarker-driven strategies where patients are selected based on specific genetic profiles such as BRCA1 or BRCA2 alterations. Pharmaceutical companies are capitalizing on this by securing approvals for PARP inhibitors in combination with anti-androgens to delay disease progression in earlier metastatic settings. According to AstraZeneca, in November 2024, in the '9M and Q3 2024 Results' report, product sales of Lynparza grew by 13% in the third quarter, confirming its sustained dominance and the rising utilization of PARP inhibition in urological oncology.

Segmental Insights

The Hormonal Therapy segment represents the fastest-growing category within the Global Genitourinary Drugs Market, primarily driven by the rising prevalence of hormone-sensitive malignancies such as prostate and ovarian cancers. As the global population ages, the demand for Androgen Deprivation Therapy to suppress disease progression has intensified significantly. Pharmaceutical developers are responding with novel oral formulations that improve patient adherence compared to traditional injectable options. Additionally, recent approvals by the U.S. Food and Drug Administration (FDA) for advanced hormonal agents have expanded treatment accessibility, further validating the segment's rapid expansion and clinical prioritization.

Regional Insights

North America currently maintains the leading position in the Global Genitourinary Drugs Market, primarily driven by the high prevalence of urological disorders such as prostate cancer, benign prostatic hyperplasia, and urinary tract infections. This dominance is reinforced by a well-established healthcare infrastructure that ensures widespread patient access to treatments through robust reimbursement frameworks. Additionally, the region benefits from strong research and development activities by major pharmaceutical companies. The United States Food and Drug Administration plays a pivotal role in this ecosystem by frequently granting regulatory approvals for novel therapies, thereby continuously expanding available treatment options.

Recent Developments

• In March 2025, GSK secured approval from the U.S. Food and Drug Administration for Blujepa, a first-in-class oral antibiotic for treating uncomplicated urinary tract infections in adult women and adolescents. This regulatory decision represented the first new oral antibiotic class for this specific indication in nearly thirty years, addressing a critical gap in patient care. The approval was founded on positive results from two pivotal Phase III trials, which showed the drug's efficacy was non-inferior or superior to standard treatments. The product launch aimed to combat increasing antimicrobial resistance and provide a necessary alternative for millions of patients suffering from these common infections.
• In August 2024, Novartis obtained accelerated approval from the U.S. Food and Drug Administration for Fabhalta, marking a significant advancement in the treatment of primary immunoglobulin A nephropathy (IgAN). As the first complement inhibitor approved for this indication, the oral medication was designed to reduce proteinuria in adults at risk of rapid disease progression. The approval was based on interim data from a Phase III study, which demonstrated a clinically meaningful 44% reduction in proteinuria compared to placebo. This development expanded the company's renal portfolio and offered a targeted therapy for a rare, progressive kidney disease with high unmet needs.
• In April 2024, ImmunityBio received approval from the U.S. Food and Drug Administration for its novel immunotherapy, Anktiva, to be used in combination with Bacillus Calmette-Guérin (BCG). This regulatory milestone authorized the treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, a condition with limited therapeutic alternatives. The approval was supported by clinical trial results showing a complete response rate of 62% among evaluable patients, with many experiencing durable responses exceeding two years. This launch introduced a first-in-class IL-15 receptor agonist to the market, providing a significant new option to potentially prevent bladder removal.
• In January 2024, Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma for a total equity value of approximately $2.0 billion. This strategic transaction allowed the company to enhance its oncology portfolio by gaining access to a proprietary platform for developing next-generation antibody-drug conjugates (ADCs). The acquisition specifically targeted the advancement of therapies for metastatic castration-resistant prostate cancer through the addition of ARX517, a promising candidate designed to target the prostate-specific membrane antigen (PSMA). The move underscored the company's commitment to delivering precision biologics that offer effective tumor elimination with potentially fewer side effects than traditional chemotherapy.

Key Market Players

• Abbott laboratories Ltd.
• Bristol-Myers Squibb Co.
• Novartis AG
• Genentech, Inc.
• F. Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals, Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Pfizer, Inc.
• AstraZeneca Plc.

By Indication	By Product	By Region
Prostate Cancer Ovarian Cancer Bladder Cancer Cervical Cancer Renal Cancer Erectile Dysfunction Urinary Tract Infections Urinary Incontinence & Overactive Bladder Sexually Transmitted Diseases Interstitial Cystitis Hematuria Benign Prostatic Hyperplasia	Hormonal Therapy Gynecological Urologicals Anti-infectives others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Genitourinary Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Genitourinary Drugs Market, By Indication:

• Prostate Cancer
• Ovarian Cancer
• Bladder Cancer
• Cervical Cancer
• Renal Cancer
• Erectile Dysfunction
• Urinary Tract Infections
• Urinary Incontinence & Overactive Bladder
• Sexually Transmitted Diseases
• Interstitial Cystitis
• Hematuria
• Benign Prostatic Hyperplasia

• Genitourinary Drugs Market, By Product:

• Hormonal Therapy
• Gynecological
• Urologicals
• Anti-infectives
• others

• Genitourinary Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE